title: Dose-dependent effects of cholecystokinin-8 on antropyloroduodenal motility, gastrointestinal hormones, appetite, and energy intake in healthy men.
abstract: CCK mediates the effects of nutrients on gastrointestinal motility and appetite. Intravenously administered CCK stimulates pyloric pressures, increases plasma PYY, and suppresses ghrelin, all of which may be important in the regulation of appetite and energy intake. The dose-related effects of exogenous CCK on gastrointestinal motility and gut hormone release, and the relationships between these effects and those on energy intake, are uncertain. We hypothesized that 1) intravenous CCK-8 would have dose-dependent effects on antropyloroduodenal (APD) pressures, plasma PYY and ghrelin concentrations, appetite, and energy intake and 2) the suppression of energy intake by CCK-8 would be related to the stimulation of pyloric motility. Ten healthy men (age 26 +/- 2 yr) were studied on four separate occasions in double-blind, randomized fashion. APD pressures, plasma PYY and ghrelin, and appetite were measured during 120-min intravenous infusions of 1) saline ("control") or 2) CCK-8 at 0.33 ("CCK0.33"), 3) 0.66 ("CCK0.66"), or 4) 2.0 ("CCK2.0") ng.kg(-1).min(-1). After 90 min, energy intake at a buffet meal was quantified. CCK-8 dose-dependently stimulated phasic and tonic pyloric pressures and plasma PYY concentrations (r > 0.70, P < 0.05) and reduced desire to eat and energy intake (r > -0.60, P < 0.05) without inducing nausea. There were relationships between basal pyloric pressure and isolated pyloric pressure waves (IPPW) with plasma CCK (r > 0.50, P < 0.01) and between energy intake with IPPW (r = -0.70, P < 0.05). Therefore, our study demonstrates that exogenous CCK-8 has dose-related effects on APD motility, plasma PYY, desire to eat, and energy intake and suggests that the suppression of energy intake is related to the stimulation of IPPW.
authors.affiliation: Univ. of Adelaide Discipline of Medicine, Royal Adelaide Hospital, North Terrace, Adelaide, SA 5000 Australia.
authors.forename: Ixchel M
authors.initials: IM
authors.lastname: Brennan
authors.forename: Tanya J
authors.initials: TJ
authors.lastname: Little
authors.forename: Kate L
authors.initials: KL
authors.lastname: Feltrin
authors.forename: Andre J P M
authors.initials: AJ
authors.lastname: Smout
authors.forename: Judith M
authors.initials: JM
authors.lastname: Wishart
authors.forename: Michael
authors.initials: M
authors.lastname: Horowitz
authors.forename: Christine
authors.initials: C
authors.lastname: Feinle-Bisset
mesh_terms: D000328:Adult; D001066:Appetite / Q000187:drug effects*; D002766:Cholecystokinin / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004386:Duodenum / Q000187:drug effects* / Q000502:physiology; D002149:Energy Intake / Q000187:drug effects*; D005768:Gastrointestinal Hormones / Q000032:analysis / Q000378:metabolism*; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006262:Health; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology*; D011312:Pressure; D011706:Pyloric Antrum / Q000187:drug effects* / Q000502:physiology; D055815:Young Adult
chemical_list: D005768:Gastrointestinal Hormones; D010446:Peptide Fragments; C410885:cholecystokinin 8; D002766:Cholecystokinin